Atlas Trials

Olaparib Maintenance With Pembrolizumab & Bevacizumab in BRCA Non-mutated Patients With Platinum-sensitive Recurrent Ovarian Cancer

Clinical trial NCT04361370 · ENROLLING_BY_INVITATION

Trial details

NCT number
NCT04361370
Sponsor
Yonsei University
Status
ENROLLING_BY_INVITATION
Phase
Phase 2
Study type
INTERVENTIONAL
Platinum-sensitive Recurrent BRCA Wild Type Ovarian Cancer
Start date
2020-10-28
Primary completion
2026-05-01
Enrollment
44

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.